2-(4-hydroxyphenyl)thiophene-3-carboxylate methyl ester | 549526-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-(4-hydroxyphenyl)thiophene-3-carboxylate methyl ester
• 英文别名: 2-(4-Hydroxy phenyl)thiophene-3-carboxylate methyl ester；methyl 2-(4-hydroxyphenyl)thiophene-3-carboxylate
• CAS: 549526-58-1
• 化学式: C₁₂H₁₀O₃S
• 分子量: 234.276
• InChiKey: UZDDROHWUMBGDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxyphenyl)thiophene-3-carboxylate methyl ester 、 二甲氨基硫代甲酰氯 在 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 以87%的产率得到2-(4-dimethylthiocarbamoyloxyphenyl)thiophene-3-carboxylate methyl ester
  参考文献：
  名称：

  EP1690538

  摘要：

  公开号：
• 作为产物：
  描述：

  2-(4-aminophenyl)thiophene-3-carboxylate methyl ester 在 硫酸 、 sodium nitrite 、 copper(II) nitrate 、 copper(II) oxide 作用下， 以 水 为溶剂， 反应 1.75h， 以46%的产率得到2-(4-hydroxyphenyl)thiophene-3-carboxylate methyl ester
  参考文献：
  名称：

  EP1690538

  摘要：

  公开号：

文献信息

• Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
  申请人：Fukui Yoshikazu

  公开号：US20070054902A1

  公开（公告）日：2007-03-08

  A compound of formula (I): (wherein R 1 -R 10 are each independently hydrogen, halogen, optionally substituted lower alkyl or the like, X 1 is —O—, —S—, —NR 11 — (wherein R 11 is hydrogen, lower alkyl or the like), —CR 12 R 13 CO—, —(CR 12 R 13 )mO—, —O(CR 12 R 13 )m- (wherein R 12 and R 13 are each independently hydrogen or lower alkyl and m is a integer between 1 and 3) or the like, X 2 is a bond, —O—, —S—, —NR 14 — (wherein R 14 is hydrogen, lower alkyl or the like, R 14 and R 6 can be taken together with the neighboring atom to form a ring) or —CR 15 R 16 — (wherein R 15 and R 16 are each independently hydrogen or lower alkyl, R 15 and R 6 or R 10 can be taken together with the neighboring carbon atom to form a ring, R 16 and R 9 can be joined together to form a bond), X 3 is COOR 17 , C(═NR 17 )NR 18 OR 19 or the like), a pharmaceutically acceptable salt or a solvate thereof.

  化合物的化学式为（I）：（其中R1-R10各自独立地为氢，卤素，可选择性取代的低碳基或类似物，X1为—O—，—S—，—NR11—（其中R11为氢，低碳基或类似物），—CR12R13CO—，—（CR12R13）mO—，—O（CR12R13）m-（其中R12和R13各自独立地为氢或低碳基，m为1到3之间的整数）或类似物，X2为键，—O—，—S—，—NR14—（其中R14为氢，低碳基或类似物，R14和R6可以与相邻的原子结合形成环）或—CR15R16—（其中R15和R16各自独立地为氢或低碳基，R15和R6或R10可以与相邻的碳原子结合形成环，R16和R9可以结合在一起形成键），X3为COOR17，C（═NR17）NR18OR19或类似物），其药学上可接受的盐或溶剂化物。
• ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1690538A1

  公开（公告）日：2006-08-16

  A compound of formula (I) : (wherein R1-R10 are each independently hydrogen, halogen, optionally substituted lower alkyl or the like, X1 is -O-, -S-, -NR11- (wherein R11 is hydrogen, lower alkyl or the like), -CR12R13CO-, -(CR12R13)mO-, -O(CR12R13)m- (wherein R12 and R13 are each independently hydrogen or lower alkyl and m is a integer between 1 and 3) or the like, X2 is a bond, -O-, -S-, -NR14- (wherein R14 is hydrogen, lower alkyl or the like, R14 and R6 can be taken together with the neighboring atom to form a ring) or -CR15R16-(wherein R15 and R16 are each independently hydrogen or lower alkyl, R15 and R6 or R10 can be taken together with the neighboring carbon atom to form a ring, R16 and R9 can be joined together to form a bond), X3 is COOR17, C( = NR17)NR18OR19 or the like), a pharmaceutically acceptable salt or a solvate thereof.

  式 (I) 的化合物： 其中 R1-R10各自独立地为氢、卤素、任选取代的低级烷基或类似物，X1为-O-、-S-、-NR11-（其中R11为氢、低级烷基或类似物）、-CR12R13CO-、-(CR12R13)mO-、-O(CR12R13)m-（其中R12和R13各自独立地为氢或低级烷基，m为1至3之间的整数）或类似物、 X2 是键、-O-、-S-、-NR14-（其中 R14 是氢、低级烷基或类似物，R14 和 R6 可与邻近原子一起形成环）或-CR15R16-（其中 R15 和 R16 各自独立地是氢或低级烷基、R15和R6或R10可与邻近的碳原子结合形成环，R16和R9可结合形成键），X3为COOR17、C( = NR17)NR18OR19或类似物），其药学上可接受的盐或溶液。
• [EN] N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'AMINE CYCLIQUE N-AROYLE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR D'OREXINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2003051368A1

  公开（公告）日：2003-06-26

  According to the invention there is provided compounds of formula (1): Wherein: X represents a bond, oxygen, NR3 or a group (CH2)n wherein n represents 1 of 2; Y represents =(CH2)qNHC(O), -(CH2)qO(CH2)p, -(CH2)qS(CH2)p, -(CH2)qC(O)(CH2)p, (CH2)qSO2(CH2)p, -(CH2)qCH=CH(CH2)p, -(CH2)pCH(OH)(CH2)p, -C(O), -(CH2)3,-(CH2)qNH, - (CH2)qNHCONK or -(CH2)qCONH; wherein q represents 1 or 2 and p represents 0 or 1; Ar1 represents a phenyl, naphthyl or 5 or 6 membered heteroaryl group containing up to 3 heteroatorns selected from N, O, and S, or a bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S any ofwhich can be optionally substituted; Ar2 represents an optionally substituted phenyl or a 5- or 6-membered'heteroaryl group containing up to 3 heteroatoms selected from N, O and S; Ar3 represents an optionally substituted R5.is-O (CH2)mNR1R2 Or (CH2)mNR1 R2 each of R1 and R2 independently represents a hydrogen atom or an optionally substituted (C1-6)alkyl group or R1 and R2 together with the nitrogen to which they are attached form part of a (C3-6)azacycloalkane or (C3-6)(2-oxo)azacycloalkane ring, or R1 with at least one CH2 of . the (CH2) m portion of the group form a (C3-6) azacycloalkane and R2 represents hydrogen, an optionally substituted (C1-6)alkyl group, piperidine, pyrrolidine, morpholine or with the nitrogen to which they are attached forms a second (C3-6)azacycloalkane fused to the first (C3-6)azacycloalkane; R3 represents hydrogen or optionally substituted (C1-6) alkyl; m represents an integer from '2 to 6; and Ar3 is attached to Ar2 ortho to the amide carbonyl group; The compounds of formula (I) and their pharmaceutically acceptable derivatives are useful for the treatment of diseases or disorders where an antagonist of a human orexin receptor is required
• EP1690538
  申请人：——

  公开号：——

  公开（公告）日：——